Bio-Modeling Systems: The Mechanisms-Based Mecidicine Company
  • 2017: PRESS-RELEASE: Paris-New-York October 4, 2017: BMSystems, with its 14 independently validated successes to date, is selected by the Galien Foundation for the MedStartUp Award 2017 program first step during the US Galien Prize Forum in New-York.
     
  • 2017: ANNOUNCEMENT: Latest news:  Press-release from Hospices Civils de Lyon about phage therapy success with Pherecydes Pharma bacteriophages. Pherecydes-Pharma, is BMSystems’ first therapeutic spin-off.
     
  • 2017: ANNOUNCEMENT: Paris September 7, 2017: The future of Medicine: Bio-Modeling Systems invited to present at the Summer Universities of Fédération Hospitalière de France
     
  • 2017: ANNOUNCEMENT: Belgium August 26-27, 2017: BMSystems selected to meet Wallonia life Sciences Companies and is invited to the Spa-Francorchamps Formula 1 Race. Great place for top meeting!

  • 2017: ANNOUNCEMENT: Paris July 4, 2017. BMSystems was invited to present at the Conference INSEAD Alumni at BCG Paris Office: Everything you always wanted to know about Digital Health revolution “big promises” but were afraid to ask!

  • 2017: ANNOUNCEMENT: Paris January 17, 2017: BMSytems was invited at the France-India healthcare Summit to present its Computer Augmented Deductive Intelligence platform and its operational successes

  • 2017: ANNOUNCEMENT: Paris January 17, 2017: BMSytems invited to present its collaborative success story with CEA life Sciences at the 10 years anniversary of Medicen Paris Region Health cluster

  • 2017: Happy New Year: Our 8 Resolutions for 2017 to be ready for the upcoming bubble explosion! - Bonne Année: Nos 8 Résolutions pour 2017
     
  • 2016: INTERVIEW (Post LinkedIn FR avec explications): "Drug Discovery and health Big Data. The enormous Bubble will explode.” (Post LinkedIn ENG with all the explanations)  Manuel GEA, CEO of BMSystems in Biotech & Finances the leading biotech sector information letter

  • 2016: ANNOUNCEMENT: Paris October 5, 2016: BMSystems' CEO invited to present its digital-biology strategy and achievements at the inaugural session of Medicen Paris Region 10th years anniversary

  • 2016: PRESS RELEASE: Paris September 5, 2016: BMSystems selected to present CADI Discovery at the Connexion R&D conference organized by COSMETIC-VALLEY the leading Perfumery & Cosmetic cluster in France.

  • 2016: ANNOUNCEMENT August 1, 2016: BIO-MODELING SYSTEMS' novel Parkinson's therapy mentioned in a Report Covering 179 Companies. A new recognition of CADI Discovery capability to generate novel therapeutic strategies in complex human diseases of which CNS

  • 2016: Updated: Inaugural Presentation Bio-Entrepreneur 2015: The future will be digital and biology, but who will lead? Google? Watson? Alone or MDs, Physiologists, Biologists educating and mastering them combining diagnostics, therapies, connected devices and IT technologies?
Bio-Modeling Systems: The Mechanisms-Based Mecidicine Companys

"Correct understanding of diseases / disorders mechanisms  is the first objective. Finding the most adapted integrated diagnostics, therapies & preventive solutions are the necessary consequences of the first objective".

Bio-Modeling Systems is the world’s first Mechanisms-Based medicine company that changed the discovery paradigm to create novel robust medical meanings from unreliable heterogeneous sources of data to generate validated & directly exploitable first in class heuristic non-mathematical mechanistic CADI™* models.

We propose to R&D & Translational Medicine Executives, robust alternative decision-making to de-risk, save time, costs, and novel cost-effective diagnostics/therapies for their businesses.

Created in 2004, profitable since 2006, thanks to our recurrent clients, we confirmed in Pharma, Biotech, Cosmetics, Nutrition and digital-Health, CADI™ Discovery capability to achieve:

  1. A world's first in neurodegenerative diseases (publication) with CEA: 2 awards in the US & Europe.

  2. Pherecydes-Pharma: BMSystems' spin-off, MR infections therapies,  3 patents, publication, world's first multi-centric clinical trial with bacteriophages in Phase I/II, Compassionate Use Success.

  3. CEA/BMSystems collaborative research in CNS that led to the co-owned patent WO201029131 with a worldwide exclusive license to Theranexus, CEA’s spin-off currently in Phase II, and

  4. 14 CADI™ successes independently validated by our clients/partners.

We warmly invite you to download our management summary,  our Short corporate Presentation or our CADI™ Discovery Concept and POCs Presentation.

 

The life-modeling issue: Are we using the right concepts in the righ order?

 

CADI™ : Computer Assisted Deductive Integration Rational